<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596749</url>
  </required_header>
  <id_info>
    <org_study_id>SIMON</org_study_id>
    <nct_id>NCT03596749</nct_id>
  </id_info>
  <brief_title>The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4</brief_title>
  <official_title>The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4: a Protocol of a Randomized, Parallel, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fan Fan Hou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate effects of sevelamer carbonate on reducing TMAO in
      stage 3b-4 CKD (pre-dialysis) patients. The study will also investigate the safety and
      tolerability of sevelamer carbonate in study population and the effects of sevelamer
      carbonate on serum p-cresyl sulfate, indoxyl sulfate, LDL-C and uric acid.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the serum concentration of TMAO between treatment group and control group</measure>
    <time_frame>22 weeks</time_frame>
    <description>The serum concentration of TMAO will be evaluated by high performance liquid chromatography (HPLC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in the serum concentration of p-cresyl sulfate between treatment group and control group</measure>
    <time_frame>22 weeks</time_frame>
    <description>The serum concentration of p-cresyl sulfate will be evaluated by high performance liquid chromatography (HPLC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the serum concentration of indoxyl sulfate between treatment group and control group</measure>
    <time_frame>22 weeks</time_frame>
    <description>The serum concentration of indoxyl sulfate will be evaluated by high performance liquid chromatography (HPLC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the serum concentration of LDL-C between treatment group and control group</measure>
    <time_frame>22 weeks</time_frame>
    <description>Chemistry evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the serum concentration of uric acid between treatment group and control group</measure>
    <time_frame>22 weeks</time_frame>
    <description>Chemistry evaluations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>CKD Stage 3b</condition>
  <condition>CKD Stage 4</condition>
  <arm_group>
    <arm_group_label>Sevelamer Carbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sevelamer carbonate will be given with fixed dose of 1600mg (p.o. b.i.d) with meals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>blank-control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer Carbonate</intervention_name>
    <description>Sevelamer carbonate 1600mg (p.o. b.i.d) with meals</description>
    <arm_group_label>Sevelamer Carbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Men or women, aged from 18 to 75 years old;

          -  2. Provide informed consent prior to enrolling in the study;

          -  3. Estimated glomerular filtration rate (eGFR) between 15-45 ml/min/1.73 m2
             (calculated by CKD-EPI equation)

        Exclusion Criteria:

          -  1. Documented poorly controlled diabetes mellitus, poorly controlled hypertension,
             malignant tumour, or any clinically significant unstable medical condition;

          -  2. Active dysphagia or swallowing disorder; or a predisposition to or current bowel
             obstruction, ileus, or severe gastrointestinal motility disorders including severe
             constipation;

          -  3. Known hypersensitivity to sevelamer or any constituents of the study drug;

          -  4. Unable to comply with the requirements of the study;

          -  5. Hypophosphatemia (serum phosphorus level &lt;0.87mmol/L);

          -  6. Women who have a positive pregnancy test at enrollment or women who are
             breast-feeding;

          -  7. Have been enrolled in other interventional study;

          -  8. Received sevelamer or other intestinal adsorbents, or broad-spectrum antibiotic
             within one month prior to the screening period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fan Fan Hou, M.D.,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of nephrology, Nanfang Hospital Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fan Fan Hou, M.D.,PhD</last_name>
    <phone>0086-20-61641591</phone>
    <email>ffhouguangzhou@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renal Division, Nanfang Hospital,Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Fan Fan Hou, M.D., Ph.D.</last_name>
      <phone>86-20-61641597</phone>
      <email>ffhou@public.guangzhou.gd.cn</email>
    </contact>
    <investigator>
      <last_name>Fan Fan Hou, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sheng Nie, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, Chen M, He Q, Liao Y, Yu X, Chen N, Zhang JE, Hu Z, Liu F, Hong D, Ma L, Liu H, Zhou X, Chen J, Pan L, Chen W, Wang W, Li X, Wang H. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012 Mar 3;379(9818):815-22. doi: 10.1016/S0140-6736(12)60033-6. Erratum in: Lancet. 2012 Aug 18;380(9842):650.</citation>
    <PMID>22386035</PMID>
  </reference>
  <reference>
    <citation>Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep 23;351(13):1296-305. Erratum in: N Engl J Med. 2008;18(4):4.</citation>
    <PMID>15385656</PMID>
  </reference>
  <reference>
    <citation>Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017 Mar 25;389(10075):1238-1252. doi: 10.1016/S0140-6736(16)32064-5. Epub 2016 Nov 23. Review.</citation>
    <PMID>27887750</PMID>
  </reference>
  <reference>
    <citation>Goto S, Yoshiya K, Kita T, Fujii H, Fukagawa M. Uremic toxins and oral adsorbents. Ther Apher Dial. 2011 Apr;15(2):132-4. doi: 10.1111/j.1744-9987.2010.00891.x. Epub 2011 Mar 8. Review.</citation>
    <PMID>21426503</PMID>
  </reference>
  <reference>
    <citation>Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, Li XS, Levison BS, Hazen SL. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015 Jan 30;116(3):448-55. doi: 10.1161/CIRCRESAHA.116.305360. Epub 2014 Nov 5.</citation>
    <PMID>25599331</PMID>
  </reference>
  <reference>
    <citation>Yubero-Serrano EM, Woodward M, Poretsky L, Vlassara H, Striker GE; AGE-less Study Group. Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. Clin J Am Soc Nephrol. 2015 May 7;10(5):759-66. doi: 10.2215/CJN.07750814. Epub 2015 Feb 20.</citation>
    <PMID>25710801</PMID>
  </reference>
  <reference>
    <citation>Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, Grosjean F, Woodward M, Striker GE. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012 Jun;7(6):934-42. doi: 10.2215/CJN.12891211. Epub 2012 Mar 29.</citation>
    <PMID>22461535</PMID>
  </reference>
  <reference>
    <citation>Rastogi A. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease. Ther Adv Cardiovasc Dis. 2013 Dec;7(6):322-42. doi: 10.1177/1753944713513061. Review.</citation>
    <PMID>24327730</PMID>
  </reference>
  <reference>
    <citation>Koopen AM, Groen AK, Nieuwdorp M. Human microbiome as therapeutic intervention target to reduce cardiovascular disease risk. Curr Opin Lipidol. 2016 Dec;27(6):615-622. Review.</citation>
    <PMID>27676197</PMID>
  </reference>
  <reference>
    <citation>GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-1259. doi: 10.1016/S0140-6736(17)32154-2. Erratum in: Lancet. 2017 Oct 28;390(10106):e38.</citation>
    <PMID>28919117</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>August 3, 2018</last_update_submitted>
  <last_update_submitted_qc>August 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nanfang Hospital of Southern Medical University</investigator_affiliation>
    <investigator_full_name>Fan Fan Hou</investigator_full_name>
    <investigator_title>Chief of Division of Nephrology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

